Pharma BD Deal Intelligence
Sumitomo Pharma Sumitovant and Myovant enter definitive agreement for $27/share acquisition.
Sumitovant completes acquisition of Myovant Sciences for $27/share total transaction value $1.7 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Sumitovant acquired remaining Myovant Sciences shares for $1.7B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sumitovant Biopharma / Myovant Sciences Ltd. (this deal) | 2022 | $1.7B | 60 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) | 2015 | $800M | 56 |
| Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA | 2013 | $305M | 16 |
| Organon & Co. / Forendo Pharma | 2021 | $954M | — |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Perrigo Company plc / HRA Pharma | 2021 | $2.1B | — |
← Browse all deals · How we score deals
More: 2022 deals · Women's Health deals